MT-7117 high dose

DRUG2 trials

Sponsors

Tanabe Pharma America, Inc.

Conditions

EPPErythropoietic Protoporphyria (EPP)XLP

Phase 2

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

CompletedNCT03520036

Tanabe Pharma America, Inc.Erythropoietic Protoporphyria (EPP)

Start: 2018-07-05End: 2019-09-28Updated: 2025-12-31

Phase 3

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

CompletedNCT04402489

Tanabe Pharma America, Inc.EPP, XLP

Start: 2020-06-01End: 2022-07-26Updated: 2025-12-30

Related Papers

Assessment of Potential Drug–Drug Interactions for Novel Oral Melanocortin‐1 Receptor Agonist Dersimelagon

Pharmacology Research & Perspectives2025-01-31

Absorption, metabolism, and excretion of [<scp><sup>14</sup>C</scp>]dersimelagon, an investigational oral selective melanocortin 1 receptor agonist, in preclinical species and healthy volunteers

Pharmacology Research & Perspectives2023-04-208 citations

Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist

European Journal of Clinical Pharmacology2023-04-159 citations

Dersimelagon in Erythropoietic Protoporphyrias

New England Journal of Medicine2023-04-1227 citations